Rawpixel.com/Shutterstock
McKesson Corporation (McKesson) has signed a consent agreement with the Competition Bureau of Canada allowing it to proceed with the acquisition of Rexall Health. McKesson expects to close the transaction, effective immediately, subject to certain closing conditions.
“We are pleased to have received regulatory approval from the Competition Bureau of Canada,” said Paul Julian, executive vice president and group president at McKesson.
“Together, McKesson and Rexall Health will continue to deliver choice and access, integrated pharmacy care and industry-leading service levels.”
When conducting its review of McKesson’s acquisition of Rexall Health, the Competition Bureau of Canada identified 26 local markets where McKesson is required to divest Rexall stores to new owners.
McKesson does not anticipate any store closures as a result of these divestitures.
McKesson Corporation, US, Rexall Health, Healthcare, Risk management, Competition Bureau of Canada, M&A, Regulation, Paul Julian
